A Phase 3 interventional study of Insulin degludec and Insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 229 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 5 that started in 2017, is one of 49 in phase 3, and was the 52nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,609 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 17th largest by enrollment of the 428 interventional ones that give a count, is one of 17 that started in 2017, is one of 187 in phase 3, and was the 434th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 1,609 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion criteria: - Male or female, age above or equal to 18 years at the time of signing . - Subjects fulfilling at least one of the below criteria (For this inclusion criterion the aim is to include minimum 80% of individuals with a previous episode of hypoglycaemia (criterion e). The remaining subjects will have to fulfil at least one of criteria a-d.): - a) Experienced at least one severe hypoglycaemic episode within the last year (according to the ADA definition, April 2013 (An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.). - b) Moderate chronic renal failure, defined as 30 - 59 mL/min/1.73 m\^2 per CKD-EPI by central laboratory analysis. - c) Hypoglycaemic symptom unawareness (History of impaired autonomic responses (tremulousness, sweating, palpitations, and hunger) during hypoglycaemia). - d) Treated with insulin for more than 5 years. - e) Episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (equal to or below 70 mg/dL [equal to or below 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening). - Subjects diagnosed (clinically) with type 2 diabetes mellitus. - Treated with basal only insulin (once daily or twice-daily insulin (insulin detemir; insulin glargine 100 U/mL, biosimilar of insulin glargine 100 U/mL or insulin Neutral Protamine Hagedorn)) equal to or above 90 days prior to the day of screening with or without any of the following anti-diabetic drugs with stable doses for equal to or above 90 days prior to screening: - a) Metformin - b) Dipeptidyl peptidase -4 inhibitor - c) Sodium-glucose co-transporter 2 inhibitor - d) Alpha-glucosidase-inhibitors (acarbose) - e) Thiazolidinediones - f) Marketed oral combination products only including the products listed in criteria 5a-5e - equal to or below 9.5% (80 mmol/mol) at screening by central laboratory analysis. - equal to or below 45 kg/m\^2. Exclusion Criteria: - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin degludec
Drug: Insulin glargine
For subcutaneous (s.c., under the skin) injection once daily
For subcutaneous (s.c., under the skin) injection once daily
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks) period. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 36 Weeks
Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks)
The observed mean daily basal insulin doses was evaluated at the end of trial (88 weeks).
Time frame: 88 weeks
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 36 weeks
Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for maintenance 2 period. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 36 weeks (maintenance 2)
Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks)
Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline to end of treatment period (week 88).
Time frame: Week 0, week 88
Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)
Change in fasting plasma glucose (FPG) was evaluated from baseline to end of treatment period (week 88).
Time frame: Week 0, week 88
Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
Participants achieving a fasting plasma glucose value of less than or equal to 7.2 mmol/L (130 mg/dL) at end of treatment (up to 88 weeks).
Time frame: At 88 weeks
Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
Participants achieving a fasting plasma glucose value of less than or equal to 5.0 mmol/L (90 mg/dL) at end of treatment (up to 88 weeks).
Time frame: At 88 weeks
Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).
Time frame: End of Treatment (up to 88 Weeks)
Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without nocturnal severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).
Time frame: At 88 weeks
Change in Mean Pre-breakfast Self-measured Plasma Glucose Used for Titration From Baseline to End of Treatment (up to 88 Weeks)
Participants measured their pre-breakfast self-measured plasma glucose (SMPG) value until end of treatment (week 88). Mean pre-breakfast self-measured plasma glucose used for titration at baseline and end of treatment (up to 88 weeks) are presented.
Time frame: Week 0, week 88
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Severe or BG confirmed symptomatic hypoglycaemia was evaluated during treatment (up to 88 weeks). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 88 weeks
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated at the end of trial (88 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 88 weeks
Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for the total trial period (88 weeks). The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
Time frame: 88 weeks
Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)
The adverse events presented are treatment emergent. A treatment-emergent AE (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last days of randomised treatment or had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last date of randomised treatment. Number of adverse events expressed in rates, from randomisation to end of maintenance period 2 (up to 88 weeks) is presented. Rate = number of events divided by patient years of exposure multiplied by 100.
Time frame: 88 weeks
Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks)
Change in body weight, measured in kilograms, from baseline (week 0) to end of treatment (week 88).
Time frame: Week 0, week 88
The trial was conducted at 230 sites in 11 countries as follows. Number of sites that screened and randomised participants to treatment are given in parenthesis. Canada:(9/9), Denmark: (6/6), Estonia: (5/5), Germany: (11 /11), Greece: (7/7), Hungary: (9/9), Norway: (4/4), Poland: (9/9), Romania: (5/4), Serbia: (8/8), United States: (157/153).
| Milestone | Insulin Degludec U200 | Insulin Glargine U300 |
|---|---|---|
| Started | 805 | 804 |
| Full analysis set | 805 | 804 |
| Safety analysis set | 802 | 798 |
| Completed | 805 | 804 |
| Not completed | 0 | 0 |
| Milestone | Insulin Degludec U200 | Insulin Glargine U300 |
|---|---|---|
| Started | 805 | 804 |
| Completed | 758 | 761 |
| Not completed | 47 | 43 |
| Withdrew: Withdrawal by subject | 36 | 36 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Subject withdrawal reason not collected | 1 | 0 |
| Milestone | Insulin Degludec U200 | Insulin Glargine U300 |
|---|---|---|
| Started | 758 | 761 |
| Completed | 733 | 734 |
| Not completed | 25 | 27 |
| Withdrew: Withdrawal by subject | 18 | 13 |
| Withdrew: Lost to follow-up | 3 | 6 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Not reconsenting | 0 | 2 |
Severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks) period. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | 216.8 | 243.9 |
The observed mean daily basal insulin doses was evaluated at the end of trial (88 weeks).
| Units | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks) | 66.6 ± 48.54 | 73.0 ± 48.48 |
Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | 62.30 | 93.75 |
Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for maintenance 2 period. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) | 0.98 | 4.88 |
Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline to end of treatment period (week 88).
| Percentage of HbA1c | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks) | -0.54 ± 0.91 | -0.46 ± 0.90 |
Change in fasting plasma glucose (FPG) was evaluated from baseline to end of treatment period (week 88).
| mg/dL | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks) | -35.50 ± 49.34 | -25.68 ± 56.69 |
Participants achieving a fasting plasma glucose value of less than or equal to 7.2 mmol/L (130 mg/dL) at end of treatment (up to 88 weeks).
| Percentage of participants | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Yes | 84.0 | 72.0 |
| No | 16.0 | 28.0 |
Participants achieving a fasting plasma glucose value of less than or equal to 5.0 mmol/L (90 mg/dL) at end of treatment (up to 88 weeks).
| Percentage of participants | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Yes | 31.5 | 21.7 |
| No | 68.5 | 78.3 |
Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).
| Percentage of participants | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Yes | 35.3 | 30.0 |
| No | 64.7 | 70.0 |
Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without nocturnal severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).
| Percentage of participants | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Yes | 47.4 | 39.3 |
| No | 52.6 | 60.7 |
Participants measured their pre-breakfast self-measured plasma glucose (SMPG) value until end of treatment (week 88). Mean pre-breakfast self-measured plasma glucose used for titration at baseline and end of treatment (up to 88 weeks) are presented.
| mmol/L | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Baseline (week 0) | 8.39 ± 2.73 | 8.41 ± 2.75 |
| End of treatment (week 88) | 5.46 ± 1.08 | 5.56 ± 1.23 |
Severe or BG confirmed symptomatic hypoglycaemia was evaluated during treatment (up to 88 weeks). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks) | 137.8 | 163.7 |
Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated at the end of trial (88 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks) | 36.93 | 60.03 |
Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for the total trial period (88 weeks). The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks) | 2.06 | 5.21 |
The adverse events presented are treatment emergent. A treatment-emergent AE (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last days of randomised treatment or had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last date of randomised treatment. Number of adverse events expressed in rates, from randomisation to end of maintenance period 2 (up to 88 weeks) is presented. Rate = number of events divided by patient years of exposure multiplied by 100.
| Episodes/(PYE*100) | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks) | 367.32 | 365.42 |
Change in body weight, measured in kilograms, from baseline (week 0) to end of treatment (week 88).
| kg | Insulin Degludec 200 | Insulin Glargine U300 |
|---|---|---|
| Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks) | 2.9 ± 5.17 | 1.7 ± 5.84 |
Collected over From the first trial-related activity after the subject had signed the informed consent until the End of Trial (week 88) + 7 days follow-up period. Results are based on the safety analysis set (SAS), which comprised all participants who received at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg U200 | 7/802 (0.9%) | 167/802 (20.8%) | 496/802 (61.8%) |
| IGlar U300 | 9/798 (1.1%) | 141/798 (17.7%) | 476/798 (59.6%) |
| Event | IDeg U200 | IGlar U300 |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 8/802 | 19/798 |
| Coronary artery diseaseCardiac disorders | 10/802 | 5/798 |
| Hypoglycaemic unconsciousnessNervous system disorders | 3/802 | 9/798 |
| PneumoniaInfections and infestations | 6/802 | 9/798 |
| Atrial fibrillationCardiac disorders | 9/802 | 5/798 |
| Acute kidney injuryRenal and urinary disorders | 4/802 | 8/798 |
| Acute myocardial infarctionCardiac disorders | 6/802 | 2/798 |
| Angina unstableCardiac disorders | 6/802 | 4/798 |
| Cardiac failure congestiveCardiac disorders | 6/802 | 3/798 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/802 | 5/798 |
| Event | IDeg U200 | IGlar U300 |
|---|---|---|
| NasopharyngitisInfections and infestations | 152/802 | 161/798 |
| Upper respiratory tract infectionInfections and infestations | 145/802 | 122/798 |
| DiarrhoeaGastrointestinal disorders | 72/802 | 79/798 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 51/802 | 65/798 |
| Back painMusculoskeletal and connective tissue disorders | 59/802 | 62/798 |
| HeadacheNervous system disorders | 51/802 | 62/798 |
| InfluenzaInfections and infestations | 59/802 | 41/798 |
| NauseaGastrointestinal disorders | 43/802 | 50/798 |
| Urinary tract infectionInfections and infestations | 49/802 | 47/798 |
| BronchitisInfections and infestations | 48/802 | 46/798 |
| Age, Continuous(Years) | Insulin Degludec U200 | Insulin Glargine U300 | Total |
|---|---|---|---|
| Mean | 62.9 ± 10 | 62.8 ± 10 | 62.8 ± 10 |
| Sex: Female, Male(Participants) | Insulin Degludec U200 | Insulin Glargine U300 | Total |
|---|---|---|---|
| Female | 333 | 368 | 701 |
| Male | 472 | 436 | 908 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec U200 | Insulin Glargine U300 | Total |
|---|---|---|---|
| Hispanic or Latino | 84 | 100 | 184 |
| Not Hispanic or Latino | 721 | 704 | 1425 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Degludec U200 | Insulin Glargine U300 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 4 | 9 |
| Asian | 25 | 29 | 54 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 78 | 65 | 143 |
| White | 693 | 699 | 1392 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 6 | 10 |
Showing the first 100 of 229 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from Mar 2017 to primary completion in Feb 2019, 23 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec